← Back to Clinical Trials
Recruiting NCT07236216

NCT07236216 Effects of tES Combined With CMDT Gait Training on Cognition, Cortical Activity, Spinal Motoneuron Excitability and Motor Performance in Stroke Individuals

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07236216
Status Recruiting
Phase
Sponsor Mahidol University
Condition Hemorrhagic Stroke
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-12-20
Primary Completion 2026-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
High-definition transcranial direct current stimulation (Active)High-definition transcranial alternating stimulation (Active)High-definition transcranial electrical stimulation (sham)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-12-20 with a primary completion date of 2026-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The present study will use transcranial electrical stimulation (tES) which are transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) combined with conventional physical therapy and cognitive-motor dual task gait training in sub-acute (at least 2 weeks after stroke onset) to chronic (within 5 years post-stroke) to investigate the effect on cortical activity, spinal motoneuron excitability, cognition and motor performance. The findings may enhance the evidence to support usages of tES for improvimg cognition, motor performance as well as cortical activity and spinal motoneuron excitability in a clinical setting.

Eligibility Criteria

Inclusion Criteria: 1. Unilateral stroke individuals aged 18-80 years. 2. A first-ever stroke. 3. Stroke onset from at least 2 weeks-5 years. 4. Able to walk independently with or without gait aids (modified Rankin scale (mRS) 1-3) 5. Montreal cognitive Assessment-Thai version (MoCA-T) greater than or equal to 20 scores. 6. Ability to read, communicate, follow and understand instructions. Exclusion Criteria: 1. Presence of any psychological or neurological antecedent, unstable medical conditions or condition that may increase risk of stimulation such as epilepsy, seizure, and history of brain injury 2. Having unstable cardiovascular disease or respiratory disease, and uncontrolled chronic disease such as diabetes mellitus (DM), hypertension (HT) and chronic kidney disease (CKD) 3. Receiving other non-invasive brain stimulation or additional intervention such as TMS, PMS or acupuncture 4. Presence of metal implantation, intracranial shunt, cochlear implantation, or cardiac pacemakers. 5. Presence of an opened wound, infectious wound around scalp or craniectomy with unreplaced bone flap 6. Moderate pain (numeric pain rating score \> 4/10) in any joint of the upper or lower limb, whether paretic or non-paretic 7. Presence of color blindness 8. Presence of any substance use including cannabis and kratom

Contact & Investigator

Central Contact

Wanalee Klomjai, PhD

✉ wanalee.klo@mahidol.edu

📞 +6624415450

Frequently Asked Questions

Who can join the NCT07236216 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hemorrhagic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07236216 currently recruiting?

Yes, NCT07236216 is actively recruiting participants. Contact the research team at wanalee.klo@mahidol.edu for enrollment information.

Where is the NCT07236216 trial being conducted?

This trial is being conducted at Nakhon Pathom, Thailand.

Who is sponsoring the NCT07236216 clinical trial?

NCT07236216 is sponsored by Mahidol University. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology